Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152232 | 0.89 | AKR1C1 (0.45) | L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3134616 | 0.86 | MEN1 (0.38) | GAAMEN1KMT2AABCC8KCNJ11 | |
| SCHEMBL4152236 | 0.86 | ALDH1A1 (0.34) | POLBL3MBTL1GAAALDH1A1NPC1 | |
| SCHEMBL23248029 | 0.81 | ALDH1A1 (0.39) | L3MBTL1GAAALDH1A1NPC1RAB9A | |
| SCHEMBL1313846 | 0.79 | AKR1C1 (0.42) | GAA | |
| SCHEMBL4322724 | 0.79 | AKR1C1 (0.38) | GAAMEN1KMT2ACYP2C9 | |
| SCHEMBL4762096 | 0.79 | — | — | |
| SCHEMBL22540389 | 0.78 | POLB (0.38) | POLBL3MBTL1GAAALDH1A1NPC1 | |
| SCHEMBL26916818 | 0.78 | AKR1C1 (0.41) | GAAMEN1KMT2A | |
| SCHEMBL4001122 | 0.76 | CYP2C9 (0.34) | POLBL3MBTL1GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041142-B1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8399503-B2 | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | GRUNENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2044016-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | AZI2, TPMT, AADAC | POLB 4256/4885L3MBTL1 4856/4885GAA 2289/4885 |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | POLB 3818/4885L3MBTL1 3675/4885GAA 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.